Identifying interferon-responsive chronic myeloid leukemia patients, by detecting significant expression of an interferon-regulatory factor

摘要

Identifying patients with chronic myeloid leukemia (CML) who are responsive to interferon (IFN) therapy comprising determining the level, in body fluids and/or tissues, of an interferon-regulatory factor (IRF), is new. Only patients with significant expression of IRF, relative to normal subjects, are given the therapy. Independent claims are also included for the following: (1) diagnostic kit for the novel method; and (2) agent for gene therapy of CML, in patients without significant expression of IRF, comprising a nucleic acid sequence that encodes IRF.